HikalQ4 FY24

Hikal Q4 FY24 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹217.94P/E: 37.8Market Cap: ₹2.7K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 3

Margin

Category 1

Fundraise

N/A

Order

N/A

Capex

Yes

2 of 3 growth signals are positive.

Full analysis

Revenue guidance

Category 3
  • Hikal targets a medium-term sales growth of 12-15% annually, driven by the pharmaceutical and crop protection segments.
  • The company expects the animal health business to contribute significantly, aiming for commercial-scale production and revenue ramp-up over 2-2.5 years post-validation.
  • Crop protection business anticipates recovery towards the end of FY25, after destocking and inventory normalization.
  • The CDMO business maintains a strong pipeline with consistent new product launches, expected to increase the CDMO share back to historical levels.
  • New multi-purpose facility and CAPEX investments (about Rs. 200+ crores) are expected to support volume growth and capacity utilization improvements starting FY25-26.
  • Growth in legacy APIs and food ingredients pipeline (expected peak around 2026) will add to revenue.
  • Overall, the company is optimistic about the medium to long-term growth potential due to supply chain shifts from China and demand recovery.

See what Hikal management said on margin guidance — free account, 30 seconds.

Fundraise plans

  • No specific mention of new fundraising through debt or equity in the provided transcript.
  • CAPEX investments are primarily funded through internal accruals and careful investment decisions.
  • Kuldeep Jain mentioned being open to investing in new CAPEX only if there is a strong business case.
  • No explicit plans or guidance about raising fresh capital through debt or equity were disclosed during the call.
  • The company is focusing on utilizing existing capacities and strategic debottlenecking to enhance growth and returns.

See what Hikal management said on order book — free account, 30 seconds.

Capex plans

Yes
  • FY24 CAPEX was about Rs.230 crores, with approximately Rs.140 crores spent on the animal health segment (page 16).
  • The animal health plant has started operations and no immediate further CAPEX is planned unless future debottlenecking or additional reactors are needed (page 16).
  • For FY25, estimated CAPEX is around Rs.100-120 crores, mainly for debottlenecking and infrastructure upgrades (page 9).
  • Beyond FY25, the company is open to CAPEX investments provided there is a strong business case (page 9).
  • Most CAPEX in recent years focused 55-60% on growth initiatives, with commercial supply starting from H2 FY26 (page 9).
  • Debottlenecking opportunities with high short-term ROI exist in food ingredients, pharma, and crop protection segments (page 9).
  • No major new CAPEX is expected next year unless big new contracts or business requirements arise (page 9).

Track Hikal — get its next earnings analysis in your feed

How does Hikal rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature
ThisHikal
Rev 3Mar 1

How does Hikal rank in Pharmaceuticals & Biotechnology?

Compare Hikal against every Pharmaceuticals & Biotechnology company (Q4 FY24) on revenue, margins and earnings-call signals.

View Pharmaceuticals & Biotechnology leaderboard →

Others in Pharmaceuticals & Biotechnology this season

  • Lasa Supergeneri (Q2 FY27)

    306.11 Lakhs in Q2 Sept 30, 2025 (over 99% decline YoY). Key results statement takeaways from Lasa Supergenerics Ltd's Q2 FY27 results statement — and how it ra

  • Themis Medicare (Q2 FY27)

    Q2 FY27 net revenue: ₹89.74 crore, up 15.1% year-on-year from ₹77.99 crore in Q2 FY26 (Page 8). Key investor presentation takeaways from Themis Medicare Ltd's Q

  • Panacea Biotec (Q2 FY27)

    September 30, 2026: ₹18,967 Lakh . Key results statement takeaways from Panacea Biotec Ltd's Q2 FY27 results statement — and how it ranks against sector peers.

  • Biofil Chemicals (Q2 FY27)

    Quarterly Revenue (Q2 ended 30/09/2026):** ₹166.87 Lakhs (Pharma Unit), ₹0.00 Lakhs (Chemicals Division); Total Gross Turnover ₹166.87 Lakhs. Key results statem

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →